Epigenetic Determinants of Cancer
Paper cited by one pathway page and one roadmap page, indexed on Europe PMC as PubMed record 27194046 and published in Cold Spring Harbor perspectives in biology; the citing pages link this DOI, which is how the record was matched.
Overview
SUMMARYEpigenetic changes are present in all human cancers and are now known to cooperate with genetic alterations to drive the cancer phenotype. These changes involve DNA methylation, histone modifiers and readers, chromatin remodelers, microRNAs, and other components of chromatin. Cancer genetics and epigenetics are inextricably linked in generating the malignant phenotype; epigenetic changes can cause mutations in genes, and, conversely, mutations are frequently observed in genes that modify the epigenome. Epigenetic therapies, in which the goal is to reverse these changes, are now one standard of care for a preleukemic disorder and form of lymphoma. The application of epigenetic therapies in the treatment of solid tumors is also emerging as a viable therapeutic route.
Indexed on Europe PMC as PubMed record 27194046 (DOI 10.1101/cshperspect.a019505). Matched by DOI alone: one pathway page and one roadmap page cite this DOI among their external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.
One pathway page and one roadmap page on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
- Matched to the citing OnCo records by DOI alone; the summary reproduces the Europe PMC abstract and no figure has been verified against the full paper.
Similar pages
not linked directly; found by shared links- TermHallmark (2022): non-mutational epigenetic reprogramming
Shares Epigenetic reprogramming, Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome.
- PathwayMutant IDH / 2-hydroxyglutarate
Shares Epigenetic reprogramming, Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome.
- PathwayMenin / KMT2A (HOXA9-MEIS1 axis)
Shares Epigenetic reprogramming, Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome.
- Key paperHallmarks of Cancer 2022: adding phenotypic plasticity, epigenetic reprogramming, microbiomes and senescent cells
Shares Epigenetic reprogramming, Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome.
- PathwaySWI/SNF chromatin remodelling
Shares Epigenetic reprogramming, Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome.
- TreatmentVorasidenib
Shares Epigenetic reprogramming, Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome.
- TreatmentZiftomenib
Shares Epigenetic reprogramming, Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome.
- TreatmentRevumenib
Shares Epigenetic reprogramming, Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome.